US Patent 7563885 Modulation of Tudor-SN expression
Patent 7563885 was granted and assigned to Ionis Pharmaceuticals on July, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+377 characters)
Article
Patent abstract
Compounds, compositions and methods are provided for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07563885 Modulation of Tudor-SN expression US Patent 7563885 Modulation of Tudor-SN expression
Infobox
Patent Number
0756388500
Patent Number
756388500
Edits on 25 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075638850
Date of Patent
July 21, 2009
0Patent Application Number
111352550
Date Filed
May 23, 2005
0Official Website
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075638850
Date of Patent
July 21, 2009
0Patent Application Number
111352550
Date Filed
May 23, 2005
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07563885 Modulation of Tudor-SN expression
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07563885
Date of patent
July 21, 2009
Patent application number
11135255
Date Filed
May 23, 2005
Patent primary examiner
Find more entities like US Patent 7563885 Modulation of Tudor-SN expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.